<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>31(4)</volume><submitter>Ludwig H</submitter><journal>Leukemia</journal><pagination>997-1000</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC5383929</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Olaptesed pegol, an anti-CXCL12/SDF-1 Spiegelmer, alone and with bortezomib-dexamethasone in relapsed/refractory multiple myeloma: a Phase IIa Study.</pubmed_title><pmcid>PMC5383929</pmcid><pubmed_authors>Leitgeb C</pubmed_authors><pubmed_authors>Vauleon S</pubmed_authors><pubmed_authors>Dummler T</pubmed_authors><pubmed_authors>Foa R</pubmed_authors><pubmed_authors>Engelhardt M</pubmed_authors><pubmed_authors>Petrucci MT</pubmed_authors><pubmed_authors>Garderet L</pubmed_authors><pubmed_authors>Weisel K</pubmed_authors><pubmed_authors>Beyer D</pubmed_authors><pubmed_authors>Greil R</pubmed_authors><pubmed_authors>Baumann M</pubmed_authors><pubmed_authors>Leleu X</pubmed_authors><pubmed_authors>Cafro AM</pubmed_authors><pubmed_authors>Ludwig H</pubmed_authors><pubmed_authors>Riecke K</pubmed_authors><pubmed_authors>Yakoub-Agha I</pubmed_authors><pubmed_authors>Zboralski D</pubmed_authors><pubmed_authors>Kruschinski A</pubmed_authors></additional><is_claimable>false</is_claimable><name>Olaptesed pegol, an anti-CXCL12/SDF-1 Spiegelmer, alone and with bortezomib-dexamethasone in relapsed/refractory multiple myeloma: a Phase IIa Study.</name><description/><dates><release>2017-01-01T00:00:00Z</release><publication>2017 Apr</publication><modification>2026-05-05T15:23:31.55Z</modification><creation>2026-04-07T21:48:14.643Z</creation></dates><accession>S-EPMC5383929</accession><cross_references><pubmed>28074071</pubmed><doi>10.1038/leu.2017.5</doi></cross_references></HashMap>